Supplementary Materials

Supplementary Material for:

Noninvasive Identification and Monitoring of Cancer Mutations by Targeted Deep Sequencing of Plasma DNA

Tim Forshew, Muhammed Murtaza, Christine Parkinson, Davina Gale, Dana W. Y. Tsui, Fiona Kaper, Sarah-Jane Dawson, Anna M. Piskorz, Mercedes Jimenez-Linan, David Bentley, James Hadfield, Andrew P. May, Carlos Caldas, James D. Brenton,* Nitzan Rosenfeld*

*To whom correspondence should be addressed. E-mail: nitzan.rosenfeld{at}cancer.org.uk (N.R.); james.brenton{at}cancer.org.uk (J.D.B.)

Published 30 May 2012, Sci. Transl. Med. 4, 136ra68 (2012)
DOI: 10.1126/scitranslmed.3003726

This PDF file includes:

  1. Methods
  2. Fig. S1. PCR strategy and primer design.
  3. Fig. S2. Sanger traces for mutations identified by tagged-amplicon sequencing.
  4. Fig. S3. Background frequencies and detection limits for base substitutions.
  5. Fig. S4. Replicate dilute Sanger sequencing of a mutation identified in plasma.
  6. Table S1. Target-specific primers.
  7. Table S2. Unique sequencing barcodes.
  8. Table S3. Mutations identified in FFPE samples.
  9. Table S4. SNPs identified in circulating DNA from two plasma control samples.
  10. Table S5. Frequency of SNP alleles in dilution series of DNA from control plasma.
  11. Table S6. Additional data for Table 2 for mutations identified in plasma samples.
  12. Table S7. Mutations and amplicons studied in one breast cancer patient.

[Download PDF]